Question 1

What is MaxCyte?

Accepted Answer

MaxCyte is a Company.

Question 2

How often does MaxCyte appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was MaxCyte first tracked by Ergen?

Accepted Answer

First tracked on Jul 21, 2026.

Question 4

When was MaxCyte last mentioned in news?

Accepted Answer

Last active on Jul 22, 2026.

Question 5

What is MaxCyte's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is MaxCyte in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving MaxCyte?

Accepted Answer

MaxCyte-Genentech cell therapy license (Jul 21, 2026, 6 articles).

Question 8

How did the "MaxCyte-Genentech cell therapy license" event impact MaxCyte?

Accepted Answer

MaxCyte is the licensor, gaining a high-profile partner in F. Hoffmann-La Roche — Genentech, which validates its technology and provides recurring revenue. The partnership enhances MaxCyte's reputation and market position in cell engineering.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.